Research1 day ago 5 min read
Meta-analysis: tesamorelin reduces visceral fat in HIV-associated lipodystrophy
Pooled data from seven trials confirms a consistent visceral fat reduction.
by Editorial team
The analysis
Researchers pooled data from seven randomized trials covering more than 1,200 patients.
All trials looked at adults with HIV-associated lipodystrophy.
Findings
Tesamorelin reduced visceral adipose tissue by an average of 15-18% versus placebo over 26 weeks.
Subcutaneous fat was largely unaffected, consistent with a targeted mechanism.
Context
Tesamorelin is FDA-approved for this specific indication.
Off-label use for general fat loss in healthy adults is not supported by this evidence.